Nur Zeinomar

1.3k citations
29 papers · 439 indexed · h-index 11
Topics
BRCA gene mutations in cancer (11 papers)Global Cancer Incidence and Screening (10 papers)Cancer Risks and Factors (8 papers)

In The Last Decade

Nur Zeinomar

26 papers receiving 433 citations

Peers

Nur Zeinomar
Comparison fields: 5 of 81
  • Oncology 211
  • Cancer Research 116
  • Genetics 96
  • Pathology and Forensic Medicine 91
  • Molecular Biology 76
Replace Salma Butt with:
Salma Butt Sweden
Andreana N. Holowatyj United States
Sungshim Lani Park United States
Daniel Mailo United States
S. A. Norman United States
V W Chen United States
D L Gao United States
MC Lin United States
Kirsti Vik Hjerkind Norway
Olga L. van der Hel Netherlands
Nur Zeinomar relative to Salma Butt Sweden Salma Butt's profile →
Citations per field
00.5×4.8×
Salma Butt · 1×
Citations per year

Countries citing papers authored by Nur Zeinomar

Since Specialization
Citations

This map shows the geographic impact of Nur Zeinomar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nur Zeinomar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nur Zeinomar more than expected).

Fields of papers citing papers by Nur Zeinomar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nur Zeinomar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nur Zeinomar. The network helps show where Nur Zeinomar may publish in the future.

Co-authorship network of co-authors of Nur Zeinomar

This figure shows the co-authorship network connecting the top 25 collaborators of Nur Zeinomar. A scholar is included among the top collaborators of Nur Zeinomar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nur Zeinomar. Nur Zeinomar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 2
3 1
4 6
5 3
6 8
7 1
8 11
9 4
10 5
11 36
12 22
13 41
14 7
15 13
16 105
17 8
18 14
19 17
20 21

About Nur Zeinomar

Nur Zeinomar is a scholar working on Oncology, Genetics and Health, Toxicology and Mutagenesis, having authored 29 papers that have together received 439 indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (11 papers), Global Cancer Incidence and Screening (10 papers) and Cancer Risks and Factors (8 papers). The work is most often cited by research in Oncology (211 citations), Cancer Research (116 citations) and Pathology and Forensic Medicine (91 citations). Nur Zeinomar has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Mary Beth Terry, Parisa Tehranifar, M. Bellanger, Roxana Moslehi, Wendy K. Chung, Sabine Oskar, Rebecca D. Kehm, Rachel T. Klein, Maegan E. Roberts and Zhixiong Xu. Their work appears in journals such as Annals of Internal Medicine, PLoS ONE and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026